Advances in prostate-specific membrane antigen-mediated antitumor drugs
10.16438/j.0513-4870.2015-0956
- VernacularTitle:前列腺特异性膜抗原介导的抗肿瘤药物研究
- Author:
Qing-zhi LÜ
1
;
Jin-cheng YANG
1
;
Yong-jun WANG
1
Author Information
1. School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
- Publication Type:REVIEWS
- Keywords:
prostate cancer;
prostate specific membrane antigen;
ligand-drug conjugate;
prodrug
- From:
Acta Pharmaceutica Sinica
2016;51(2):234-
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer is the most prevalent male malignancy in the United States, and remains the second leading cause of cancer-related death in the male population. Prostate specific membrane antigen (PSMA) is a type of Ⅱ transmembrane glycoproteins that is over-expressed in prostate cancer cell. More importantly, its expression is increased with cancer progression. PSMA has been a major target for imaging and therapeutic applications in prostate cancer. PSMA, also known as N-acetylated α-linked acidic dipeptidase Ⅰ and folate hydrolase, can catalyze the hydrolysis of α-or γ-linked glutamates from peptides or small molecules. This article provides a review of the recent applications of ligand-drug conjugates targeting PSMA and prodrugs activated by PSMA.
